Hasan E. Baysal
Leuven, VLG 3001, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Unleashing the Potential of Raman Spectroscopy to Estimate PEDOT:PSS Doping Level and Crystalline Morphology.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: July 21, 2025
Omnidirectional 3D Printing of PEDOT: PSS Aerogels with Tunable Electromechanical Performance: A Playground for Unconventional Stretchable Interconnects and Thermoelectrics.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: October 07, 2024
Facile Fabrication of Flexible and High-Performing Thermoelectrics by Direct Laser Printing on Plastic Foil.
Journal: Advanced materials (Deerfield Beach, Fla.)
Published: August 07, 2023
Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity.
Journal: Cancer drug resistance (Alhambra, Calif.)
Published: June 14, 2023
The prognostic impact of the immune signature in head and neck squamous cell carcinoma.
Journal: Frontiers in immunology
Published: July 22, 2022
Roughness-dependent clogging of particle suspensions flowing into a constriction.
Journal: Soft matter
Published: July 28, 2021
The Right Partner in Crime: Unlocking the Potential of the Anti-EGFR Antibody Cetuximab via Combination With Natural Killer Cell Chartering Immunotherapeutic Strategies.
Journal: Frontiers in immunology
Published: July 06, 2021
The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy.
Journal: Frontiers in oncology
Published: April 20, 2021
Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma.
Journal: Medicinal research reviews
Published: August 26, 2020
Cetuximab-induced natural killer cell cytotoxicity in head and neck squamous cell carcinoma cell lines: investigation of the role of cetuximab sensitivity and HPV status.
Journal: British journal of cancer
Published: January 27, 2020
Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib.
Journal: Cancers
Published: December 04, 2018
Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.
Journal: Molecular oncology
Published: November 20, 2017
Last Updated: 09/26/2026